<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879539</url>
  </required_header>
  <id_info>
    <org_study_id>CRC5607</org_study_id>
    <nct_id>NCT02879539</nct_id>
  </id_info>
  <brief_title>Cochlear Implant Low Power Strategy</brief_title>
  <official_title>Clinical Assessment of a Low Power Strategy for Cochlear Implant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hearing Cooperative Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Victoria Eye and Ear Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hearing Cooperative Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reducing power consumption in the cochlear implant is crucial to the development of future&#xD;
      smaller sound processors. The commercial MP3000 sound coding strategy has been shown to be&#xD;
      more efficient in power consumption to the standard ACE strategy. However in order to develop&#xD;
      smaller sound processors, further battery life power savings are required. The aim of this&#xD;
      study is to evaluate three experimental sets of MP3000 parameter sets, compared against the&#xD;
      default ACE program. In the background for each of the four strategies, experimental noise&#xD;
      reduction programs (SpatialNR and NR3) will also be in use. In an additional phase of the&#xD;
      study, low stimulation rate ACE programs will also be evaluated against the default&#xD;
      stimulation rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">January 27, 2017</completion_date>
  <primary_completion_date type="Actual">January 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Word recognition scores in quiet</measure>
    <time_frame>Testing over 18 weeks</time_frame>
    <description>Word recognition scores in quiet for i) MP3000 strategy compared to default ACE strategy and ii) lower rate stimulation for ACE strategy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sentence recognition scores in quiet</measure>
    <time_frame>Testing over 18 weeks</time_frame>
    <description>Sentence recognition scores in quiet for i) MP3000 strategy compared to ACE strategy and ii) lower rate stimulation for ACE strategy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fundamental frequency (F0) discrimination</measure>
    <time_frame>Testing over 18 weeks</time_frame>
    <description>F0 discrimination for MP3000 strategy compared to the ACE baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech intelligibility and helpfulness subjective ratings</measure>
    <time_frame>Testing over 18 weeks</time_frame>
    <description>For MP3000 strategy compared to the default ACE baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentence in noise scores</measure>
    <time_frame>Testing over 18 weeks</time_frame>
    <description>Comparison of MP3000 program with Spatial NR and NR3 enabled versus disabled.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hearing Loss</condition>
  <arm_group>
    <arm_group_label>MP3000-ACE strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MP3000 sound coding strategy or ACE strategy with lower stimulation rate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MP3000 sound coding strategy or ACE strategy with lower stimulation</intervention_name>
    <arm_group_label>MP3000-ACE strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (&gt;18 years) cochlear implant recipients&#xD;
&#xD;
          2. Implanted with the CI500, CI24RE and Nucleus 24 Series and CI422 cochlear implants.&#xD;
&#xD;
          3. User of commercially available Freedom, CP810 or CP900 series sound processor&#xD;
&#xD;
          4. User of the ACE strategy or MP3000 strategy&#xD;
&#xD;
          5. At least 3 months experience with the cochlear implant&#xD;
&#xD;
          6. Native speaker in the language used to assess speech perception performance&#xD;
&#xD;
          7. Willingness to participate in and to comply with all requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Additional handicaps that would prevent participation in evaluations&#xD;
&#xD;
          2. Unrealistic expectations on the part of the subject, regarding the possible benefits,&#xD;
             risks and limitations that are inherent to the procedure and investigational device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The HEARing CRC</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 21, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cochlear implants, power consumption,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

